Emergent Biosolutions
EBS
205 hedge funds and large institutions have $1.29B invested in Emergent Biosolutions in 2015 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 81 increasing their positions, 69 reducing their positions, and 24 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
43% more capital invested
Capital invested by funds: $907M → $1.29B (+$387M)
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
17% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 69
3% more funds holding
Funds holding: 199 → 205 (+6)
0.98% more ownership
Funds ownership: 84.06% → 85.03% (+0.98%)
56% less call options, than puts
Call options by funds: $545K | Put options by funds: $1.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.5M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$16.9M |
| 3 |
GAM
Gotham Asset Management
New York
|
+$15.6M |
| 4 |
SCM
Snyder Capital Management
San Francisco,
California
|
+$11.5M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$33.1M |
| 2 |
Bank of New York Mellon
New York
|
-$17.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$15.9M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$10M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$6.91M |
EBS Hedge Fund Activity: Q4 2015 in Review
205 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2015, worth a combined $1.29B — up 43% from $907M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new EBS positions and 24 closed out — a net gain of 8 holders — while 81 added to existing stakes and 69 trimmed.
The largest buyer was Vanguard Group, adding an estimated $19.5M. The largest seller was Broadfin Capital, cutting an estimated $33.1M.
- 205 institutional investors held Emergent Biosolutions (EBS) as of Q4 2015, up from 199 in Q3 2015.
- Funds reported $1.29B of Emergent Biosolutions stock for Q4 2015, up 43% quarter-over-quarter.
- 32 funds opened new Emergent Biosolutions positions in Q4 2015 and 24 closed out, a net change of +8 holders.
- The largest Emergent Biosolutions buyer in Q4 2015 was Vanguard Group, an estimated $19.5M added.
- The largest Emergent Biosolutions seller in Q4 2015 was Broadfin Capital, an estimated $33.1M sold.
Based on aggregated 13F filings for Q4 2015.